

Expert Reviews



Welcome Guest user | [Log in](#) | [Athens Login](#) | [Shibboleth Login](#) | [Register](#)

Home	Browse Journals	Search Journals	Contact Us	About Us	My Profile
----------------------	---------------------------------	---------------------------------	----------------------------	--------------------------	----------------------------

Journals
Expert Review series
Resources
Register
For Authors
For Librarians
For Advertisers
Services
Subscriptions/Pricing
Reprints
Advertising
Press Releases/News
Help
Downloads/Links
2008/9 Catalogue
Library Recommendation

Summary

Expert Review of Anticancer Therapy

November 2008, Vol. 8, No. 11, Pages 1781-1786
(doi:10.1586/14737140.8.11.1781)

Association between response to primary treatments and MGMT status in glioblastoma

Enrico Franceschi[†], Alicia Tosoni, Eugenio Pozzati and Alba A Brandes

[†] Author for correspondence

The median overall survival and, more importantly, the 2-year survival rate of patients with newly diagnosed glioblastoma are increased by the administration of combined temozolomide and radiotherapy, which has recently become the new standard of treatment in patients with a histological confirmation of diagnosis. Moreover, the assessment of O⁶-methylguanine-DNA methyltransferase gene promoter methylation has clarified the impact of this approach, and improved upon the interpretation of doubtful cases after concurrent radiotherapy/ temozolomide treatment. Therefore, future strategies in the treatment of glioblastoma patients will include stratification for MGMT methylation status, and various approaches based on epigenetic features are currently under investigation.

[Full Text](#) | [PDF \(222 KB\)](#) | [PDF Plus \(276 KB\)](#)

Users who read this text article also read:

Combination therapy for malignant glioma based on PTEN status

[Javier Gonzalez](#), [John de Groot](#)

Expert Review of Anticancer Therapy, Nov 2008, Vol. 8, No. 11, Pages 1767-1779.
[Summary](#) | [Full Text](#) | [PDF \(1248 KB\)](#) | [PDF Plus \(1233 KB\)](#) | [Add to Favorites](#) | [Related](#)

Sunitinib (SUTENT®) for the treatment of metastatic renal cell carcinoma

[Thomas E Hutson](#)

Expert Review of Anticancer Therapy, Nov 2008, Vol. 8, No. 11, Pages 1723-1731.
[Summary](#) | [Full Text](#) | [PDF \(399 KB\)](#) | [PDF Plus \(408 KB\)](#) | [Add to Favorites](#) | [Related](#)

Bevacizumab in the treatment of breast cancer

[Bhawna Sirohi](#), [Katy Smith](#)

Expert Review of Anticancer Therapy, Oct 2008, Vol. 8, No. 10, Pages 1559-1568.
[Summary](#) | [Full Text](#) | [PDF \(358 KB\)](#) | [PDF Plus \(392 KB\)](#) | [Add to Favorites](#) | [Related](#)

Targeting the endothelin system: novel therapeutic options in gynecological, urological and breast cancers

[Martin Smollich](#), [Pia Wülfing](#)

Expert Review of Anticancer Therapy, Sep 2008, Vol. 8, No. 9, Pages 1481-1493.
[Summary](#) | [Full Text](#) | [PDF \(319 KB\)](#) | [PDF Plus \(437 KB\)](#) | [Add to Favorites](#) | [Related](#)

[Home](#) > [Journal home](#) > [TOC](#) > [Summary](#)

[Prev. Article](#) | [Next Article](#)

[View/Print PDF \(222 KB\)](#)

[View PDF Plus \(276 KB\)](#)

[Add to favorites](#)

[Email to a friend](#)

[RSS](#) | [TOC Alert](#) | [Citation Alert](#)

[What is RSS?](#)

Quick Links

- [PubMed Citation](#)
- Alert me when:
[New articles cite this article](#)
- [Download to citation manager](#)
- Related articles found in:
[Expert Reviews](#), [PubMed](#)
- [View Most Downloaded Articles](#)

Quick Search

Expert Reviews for

Authors:

- Enrico Franceschi
 Alicia Tosoni
 Eugenio Pozzati
 Alba A Brandes

Keywords:

- glioblastoma
 MGMT
 radiotherapy
 temozolomide

[Home](#) | [Browse Journals](#) | [Search Journals](#) | [Contact Us](#) | [About Us](#) | [My Profile](#)
[Register](#) | [For Authors](#) | [For Librarians](#) | [For Advertisers](#) | [Subscriptions and Pricing](#) | [Reprints and Supplements](#) | [Advertising](#) | [Press Releases and News](#) | [Help](#)



Expert Reviews Ltd, Unitec House, 2 Albert Place, London, N3 1QB, UK
Business Office: Tel +44 (0)20 8371 6080 - Fax +44 (0)20 8371 6099
Editorial Office: Tel +44 (0)20 8371 6090 - Fax +44 (0)20 8343 2313
We welcome your Feedback. See our [Privacy Statement](#) and [Terms and Conditions](#).